| Authors: |
Lopez JS; Drug Development Unit, Institute of Cancer Research and the Royal Marsden Hospital, London SW7 3RP, UK. Electronic address: juanita.lopez@icr.ac.uk., Milhem M; Department of Internal Medicine, Division of Hematology/Oncology and BMT, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA., Butler MO; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto M5G 2M9, ON, Canada; Departments of Medicine and Immunology, University of Toronto, Toronto M5G 2M9, ON, Canada., Thistlethwaite F; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester M20 4GJ, UK; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, UK., Van Tine BA; Division of Oncology, Washington University in St. Louis School of Medicine, St. Louis, MO 63110, USA., D'Angelo SP; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA., Johnson ML; Lung Cancer Research Program, Sarah Cannon Research Institute at Tennessee Oncology, Nashville, TN 37203, USA., Sato T; Department of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center, Jefferson University, Philadelphia, PA 19107, USA., Arkenau HT; Phase-1 Trials Unit, Sarah Cannon Research Institute, UCL Cancer Institute, University College London, London W1G 6AD, UK., Edukulla R; Biometrics, Immunocore, Gaithersburg, MD 20878 USA., Wustner J; Translational Medicine, Immunocore, Conshohocken, PA 19428 USA., Marshall S; Clinical Development, Immunocore, Gaithersburg, MD 20878 USA., Rodon J; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston 77030, TX, USA. |
